Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.32 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310201 | 0.95 | MAP4K1 (0.32) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24309929 | 0.91 | MAP4K1 (0.33) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24310416 | 0.90 | USP1 (0.32) | MAP4K1MAP4K3KDRBRAFPTK2 | |
| SCHEMBL24310088 | 0.90 | IGF1R (0.31) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24310733 | 0.89 | IGF1R (0.34) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24309840 | 0.89 | MAP4K1 (0.32) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24309841 | 0.88 | PTK2 (0.34) | MAP4K1KDRPTK2FLT4 | |
| SCHEMBL24309869 | 0.87 | CHEK1 (0.33) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24309897 | 0.86 | DHODH (0.32) | MAP4K1MAP4K3IGF1R | |
| SCHEMBL24310392 | 0.85 | MAP4K1 (0.35) | MAP4K1MAP4K3KDRBRAFPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |